Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia.
about
Doxorubicin cardiomyopathySingle cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemiaLong-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response.Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapyEffects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer ActivityTreatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicinHow I treat children and adolescents with acute promyelocytic leukaemia.Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis.Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin.Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up.Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy.Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice.
P2860
Q24606920-A9C35319-F2AD-4C88-AB1C-4E7E4EB7B64BQ33710730-25B23A69-5009-4035-B7C0-A059D851FAF9Q34128868-84DA9E3A-A8DA-4E93-A857-BA3D9A088A30Q34292480-D218FDC4-EEEE-4388-8F14-D61AB286A7E7Q35537150-A2D5DF11-7308-4EE2-B643-A955D320091DQ36199841-E031DA04-4774-4F0B-8F29-9DAE61F1F63AQ36430103-C30F120E-3E3C-4329-8656-1B0D934A565BQ36568908-F6B3FC54-CC33-4872-B3C3-E5A0124D258FQ36938551-FCFB008A-B643-491E-9C6D-C06C2F68D689Q37451376-36679419-1B33-4B75-A1E3-B073AD6A16B2Q37712353-1F33D28D-C92C-46E4-AD27-124034DE121FQ38798789-E602AAF3-9FA3-4B8F-AA8A-0F4C20D65979Q38815519-D3FFF554-E516-48C3-A150-459B9024260DQ40413191-42A78568-1FE1-4D6C-8EB0-0FFA16760164Q41449379-50047538-14D0-452D-BADF-FC160A06CF55Q44908679-EBA47074-416B-45F2-9416-BFC37F6CFE95Q46165728-14D02EDB-0949-401A-BC24-72B9D07807B1Q46717362-50AB6822-97F5-4029-ADEA-DD3147FDBF72
P2860
Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Anthracycline-related toxicity ...... acute promyelocytic leukemia.
@en
Anthracycline-related toxicity ...... acute promyelocytic leukemia.
@nl
type
label
Anthracycline-related toxicity ...... acute promyelocytic leukemia.
@en
Anthracycline-related toxicity ...... acute promyelocytic leukemia.
@nl
prefLabel
Anthracycline-related toxicity ...... acute promyelocytic leukemia.
@en
Anthracycline-related toxicity ...... acute promyelocytic leukemia.
@nl
P2093
P1433
P1476
Anthracycline-related toxicity ...... acute promyelocytic leukemia.
@en
P2093
P304
P356
10.1007/S00277-002-0534-8
P577
2002-09-21T00:00:00Z